罗沙司他联合重组人促红素对血液透析患者疗效评估和血压的影响  

The therapeutic effect and blood pressure impact of Roxadustat combined with recombinant human erythropoietin in hemodialysis patients

作　　者：宗慧敏 宋洁 严陈燕 朱江 袁自静 王栖栖 Zong Huimin;Song Jie;Yan Chenyan;Zhu Jiang;Yuan Zijing;Wang Xixi(Department of Nephrology,Jiangning Clinical Medical College,Kangda College of Nanjing Medical University,Nanjing 211100,China)

机构地区：[1]南京医科大学康达学院江宁临床医学院肾内科,南京211100

出　　处：《国际移植与血液净化杂志》2025年第1期1-3,共3页International Journal of Transplantation and Hemopurification

基　　金：南京医科大学康达学院科研发展基金课题一般项目(KD2023KYJJ259)。

摘　　要：目的探讨罗沙司他联合重组人促红素(recombinant human erythropoietin, rhEPO)对血液透析患者肾性贫血和血压的影响。方法选取2023年3月至2023年12月在南京市江宁医院血透中心治疗的101例血红蛋白(hemoglobin, Hb)未达标的血液透析患者作为研究对象, 根据治疗药物不同分为两组, 对比两组患者临床疗效和血压情况。结果治疗后, 观察组患者Hb、红细胞比容、Hb达标率高于对照组(P<0.05);治疗后, 观察组患者收缩压、收缩压标准差、收缩压变异系数低于对照组, 血压达标率高于对照组(P<0.05)。结论与单用rhEPO治疗相比, 罗沙司他联合rhEPO治疗贫血效果更佳, 有利于血液透析患者血压的稳定和控制。Objective To explore the therapeutic effect and blood pressure(BP)impact of Roxadustat combined with recombinant human erythropoietin(rhEPO)in hemodialysis patients.Methods A total of 101 hemodialysis patients who did not meet the hemoglobin(Hb)standard at the hemodialysis center of Jiangning Clinical Medical College,Kangda College of Nanjing Medical University from March 2023 to December 2023 were enrolled in this study,and were divided into two groups according to the treatment.The clinical efficacy and BP indicators were compared between two groups.Results After treatment,the Hb compliance rate,Hb,hematocrit and the BP compliance rate in the observation group were higher than those in the control group,and the systolic BP,standard deviation of systolic BP and coefficient of variation of systolic BP were lower than those in the control group(P<0.05).Conclusion The combination of Roxadustat and rhEPO has a better therapeutic effect on renal anemia,and it is beneficial for the stability and control of BP in HD patients.

关 键 词：罗沙司他 重组人促红素 血液透析 肾性贫血 血压 

分 类 号：R692.5[医药卫生—泌尿科学]